Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Down 57.4% in May

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a large decrease in short interest during the month of May. As of May 15th, there was short interest totaling 19,598 shares, a decrease of 57.4% from the April 30th total of 46,010 shares. Currently, 0.4% of the shares of the stock are sold short. Based on an average trading volume of 28,089 shares, the short-interest ratio is currently 0.7 days.

Analyst Ratings Changes

A number of analysts have commented on the stock. HC Wainwright downgraded shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Zacks Research upgraded shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Stock Performance

Shares of NASDAQ NEUP traded down $0.01 during midday trading on Monday, reaching $5.30. 38,233 shares of the stock were exchanged, compared to its average volume of 46,607. The company has a 50 day simple moving average of $4.84 and a 200 day simple moving average of $4.44. The stock has a market capitalization of $28.62 million, a P/E ratio of -0.48 and a beta of 0.72. Neuphoria Therapeutics has a twelve month low of $3.64 and a twelve month high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.47. On average, research analysts expect that Neuphoria Therapeutics will post -4.07 earnings per share for the current year.

Institutional Trading of Neuphoria Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC acquired a new stake in Neuphoria Therapeutics in the 4th quarter valued at approximately $43,000. XTX Topco Ltd acquired a new stake in Neuphoria Therapeutics in the 4th quarter valued at approximately $47,000. Persistent Asset Partners Ltd increased its holdings in Neuphoria Therapeutics by 173.1% in the 4th quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after purchasing an additional 8,495 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in Neuphoria Therapeutics in the 4th quarter valued at approximately $54,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Neuphoria Therapeutics in the 4th quarter valued at approximately $57,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.